Tag Archives: LSN

Hot Investor Mandate 2: Healthcare-Focused VC and PE Fund Invests in North American Companies in Therapeutics, Medical Devices, Digital Health and Services

5 Apr

A private equity and venture fund is currently focused on health care investments such as therapeutics, medical devices, health care services, and digital health companies. The firm likes to invest early, generally seed-series A, as one of the earliest investors, and be involved throughout the life of the company, helping it grow and develop. The firm invests primarily in companies in North America. The firm will generally invest $250,000-$2M in the initial investment, with the potential for continuing funding. Because the firm prefers to play an active role in their portfolio companies, the firm will only invest in a limited number of companies at any given time.

The firm primarily invests in therapeutics and medical devices. Because the firm prefers to invest early, they look at companies that are still pre-clinical/in development and, for devices, will consider PMA as well as 510k devices. The firm is indication agnostic, focusing on technologies that inspire their passion. The firm will consider investing in technologies related to orphan diseases.

The firm has no specific management team requirements. Due to the firm’s active role in their portfolio companies, the firm does like to take a board seat following the investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , , , , ,

Hot Investor Mandate 3: Technology Firm Establishes New Venture Fund for Investing in Early-Stage Digital Health Companies Globally

5 Apr

An operating group of a global public technology firm with an $18B market cap. The group began its venture portfolio in 2018 with investments in B-to-B software companies targeted at specific vertical markets such as healthcare. The fund invests $0.5M – 1M per company and is seeking companies raising seed to Series B rounds. The company is seeking 5 – 10 new investments to build their initial portfolio. The company prefers companies based in Canada, though as the parent firm is located in the US, UK, EU, and AU, the fund is open to invest globally.

The company is seeking healthcare IT, and they are particularly investing in technologies with a software component. The firm prefers commercial-stage companies, though is open to looking at clinical-stage companies as well. The company is indication agnostic.

The company will help companies fill management team positions, if necessary. The company prefers companies that are generating $100K – 3M in annual revenue.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , ,

Hot Investor Mandate 4: USA and China-Based Biotech Company Seeks to Invest in Life Science Companies, with Focus on Cell/Gene Therapies, Antibodies, Synthetic Biology, etc.

5 Apr

A public biotech company with headquarters in USA and China is actively seeking for investment, partnering and acquisition opportunities to expand the company’s business in multiple areas. The firm usually invests as a strategic investor in as early as seed rounds. Typical allocations are $1-5 M.

The firm’s sectors of focus are cell and gene therapies, antibody therapeutics, life science tools, drug discovery technologies, synthetic biology technologies and industrial enzyme products.

The firm may seek a board seat depending upon size of investment. The firm is open to working with all stages of management teams and may lead or co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , , , , ,

Hot Investor Mandate 1: France-Based VC Initially Invests Up to $15M in Eary-Stage Therapeutics and Medical Device Companies

29 Mar

A venture capital firm based in Paris, France invests in early stage life science companies and seeks to be the first institutional investor in a company. The firm has raised numerous funds to date and currently has approximately €1.4 billion AUM. The firm is currently investing from its recent fund of €300M. The firm makes seed and venture investments, oftentimes investing in a company’s seed round and later leading the Company’s A round. The firm can allocate €1-15M initially and up to € 30 M over the life of the investment.

The firm is currently looking for biotech therapeutics and medical devices and tends to steer away from service companies. For therapeutics, the firm is agnostic in terms of subsector and invests in small molecule, biologics, cell and gene therapy, etc. The firm is also indication agnostic, but currently most interested in oncology (especially CAR-T assets), immunology/inflammation, CNS/neurology (with a particular interest in rare neuro conditions). The firm will consider products as early as 24-months from IND through to Phase III. For medical devices, the firm seeks paradigm-shifting technologies that can reach a human proof-of-concept stage in a relatively short period of time, and prefers PMA regulatory pathways although is open to other regulatory pathways as well.

The firm prefers to lead or co-lead an investment and generally requires a board seat in its portfolio companies. The firm seeks outstanding entrepreneurial management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , ,

Hot Investor Mandate 2: Strategic Venture Fund of a Japanese Pharma Seeks to Invest in First-In-Class Therapeutics Opportunities, with Strong Focus in Oncology

29 Mar

A strategic corporate venture capital fund by a full-fledged oncology pharmaceutical company headquartered in Tokyo, Japan, seeks to make equity investment in startup companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients. Investment size can be flexible depending on the deal. The firm will also consider the option-type of investments and spin-outs, in addition to pure equity investments. The fund is currently seeking opportunities in the USA, Europe and Japan, the focus being mainly in USA and Europe.

The firm will consider early-stage (generally research to pre-IND) first-in-class/new biology-based approaches in drug discovery and innovative platform technologies for drug discovery, especially assets that have a strategic angle to the pharmaceutical’s pipeline. The firm considers a wide variety of modalities (biologics/oncolytic viruses and small molecules) as well as cell and gene therapy, on an opportunistic basis. The firm’s primary indication of interest is oncology, but the firm is also interested in immunology, allergy, musculoskeletal, and orphan indications.

While the firm is primarily focused on therapeutics, the firm may review technologies in medical device, diagnostic, or digital health sectors if there is a strong strategic alignment.

The firm is looking for teams with strong sector expertise. With the support of the pharmaceutical’s established expertise in the field of oncology product discovery and development, the firm will provide financial resources and company outreach to build strategic alliances to help translate novel research and high potential drug candidates into cornerstone products. The firm may request regional option or rights on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , , , ,

Hot Investor Mandate 3: PE Firm with Offices in North America Invests & Provides Advisory Support to Medical and Surgical Devices and Healthcare IT Companies

29 Mar

A private equity firm founded in 2014 with offices in USA and Canada manages a fund that provides equity and equity-like investments in high growth companies in healthcare technology verticals. The size of investments generally fall under the range of $2-5 M per company, and the firm seeks to make 2-3 investments per year.

The firm works closely with clients of the firm’s advisory arm that provides companies with financial, strategic, and growth consulting and transaction advisory services including M&A. The firm will also help companies through regulatory approvals and developing new strategic and financial partnerships. The firm will consider companies that are outside of this network, but it is important that these companies form a close long-term relationship with the firm in leveraging their development. This integrated network provides for superior insight and strategy of lower risk. The firm looks globally with a strong focus in North America.

The firm is interested in highly innovative medical and surgical device companies, healthcare IT, healthcare services. The firm will not consider products in pharma or biotech industries. Medical device products should be patented and on the cusp of FDA clearance. The firm will support all classes of medical devices including 510k and PMA regulatory pathways. Healthcare IT companies are expected to demonstrate market traction prior to investment.

The firm seeks to work with companies with an experienced, motivated management team. The firm can act as the lead investor in all financing rounds, and requires a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , , ,

Hot Investor Mandate 4: Global Organization Provides Seed Capital to Early-Stage Healthcare Technologies Applicable to Emerging Markets

29 Mar

A global charity organization with an established footprint in over 100 countries worldwide, dedicated to tackling the problem of poverty and injustice, has launched a new initiative through its Canada operations. In 2016, the organization built an investment team to support entrepreneurs developing innovative technologies for emerging markets. Currently, this is the organization’s only operation with an investment vehicle.
The organization seeks to invest up to $250K in early-stage social innovations. In addition to providing capital, the organization will take an active role in helping entrepreneurs with growing their companies and providing valuable connections through their global reach.

The organization will consider any early-stage technology in the healthcare sectors that can help address and solve problems in emerging countries, with a high potential for social impact.

The organization does not have specific management team requirements, but prior experience in working with or developing technologies for emerging countries is a plus.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , , ,

← Older Entries
Newer Entries →